TEEPLE, A.; MUSER, E. Cost per Responder Analysis of Guselkumab Versus Certolizumab Pegol Using Efficacy Results from Pivotal Clinical Trials in Patients with Moderate to Severe Plaque Psoriasis. SKIN The Journal of Cutaneous Medicine, [S. l.], v. 2, p. S80, 2018. DOI: 10.25251/skin.2.supp.81. Disponível em: https://jofskin.org/index.php/skin/article/view/477. Acesso em: 22 jul. 2024.